The TappAlpha S&P 500 Growth & Daily Income ETF (TSPY) was downgraded to Hold because it has underperformed compared to similar ETFs, including those with continuous and 0DTE options strategies. Despite its lower expenses and reduced payout ratio, TSPY has not delivered better returns or superior protection during recent market stress. In a stable, low-volatility market, other continuous call writing ETFs like SPYI or GPIX offer better risk-adjusted returns. This downgrade signals investors should reconsider TSPY's role in their portfolios given its recent lackluster performance and risk management.
The TappAlpha S&P 500 Growth & Daily Income ETF (TSPY) is the subject, with Pluang market data providing context. For readers following US stocks on Pluang as of Oct 16, 2026 14:51 WIB: out of 150 priced stocks, 95 rose and 50 fell. Among notable movers, Lumen Technologies Inc (LUMN) rose 1.33% to USD 4.93 with balanced buy/sell activity and a typical hold time of 40 days, contrasting with Salesforce Inc (CRM) which rose 1.23% to USD 249.78 but saw 94% sell orders and a longer hold time of 89 days.
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
